Katharina Fritzen1, Bettina Gutschek2, Benedikte Coucke3, Katerina Zakrzewska4, Michael Hummel5, Oliver Schnell1,5. 1. 1 Sciarc Institute, Baierbrunn, Germany. 2. 2 Johnson & Johnson Medical GmbH, Neuss, Germany. 3. 3 Johnson & Johnson Medical GmbH, Beerse, Belgium. 4. 4 Johnson & Johnson Diabetes Care Companies, Cilag GmbH Int, Zug, Switzerland. 5. 5 Forschergruppe Diabetes e.V., Helmholtz Centre Munich, Munich-Neuherberg, Germany.
Abstract
BACKGROUND: Self-monitoring of blood glucose (SMBG) using the ColourSure™ Technology to visualize target range showed improvement of metabolic control and overall diabetes self-management in insulin-treated patients. This economic analysis aimed to identify cost savings for the German health system resulting from an HbA1c reduction due to the utilization of user-friendly glucose meters. METHODS: Patient data from a recently published observational study on SMBG were used for risk evaluations using the UKPDS risk engine. These values were integrated in an economic analysis regarding costs of myocardial infarctions (MIs) related to diabetes for the German health system. Based on an earlier assessment these calculations were combined with a 10% reduction of severe hypoglycemic episodes. In the current study, 0% severe hypoglycemic episodes were observed. RESULTS: An HbA1c reduction of 0.69% over 6 months was associated with a 3% decreased risk of MI in 10 years. In this model the decrease led to cost savings of €4.90 per patient-year. Considering 2.3 million insulin-treated patients in Germany, this 3% reduction of MI could result in annual savings of €11.27 million. Combining this with a 10% reduction in severe hypoglycemic events, the cost savings would increase to €30.61 per patient-year or €70.4 million for 2.3 million insulin-treated patients in Germany. CONCLUSION: The improvement of metabolic control and diabetes self-management that was achieved with the ColourSure™ Technology has the potential to generate substantial cost savings for the German health system underlining the importance of user-friendly methods for SMBG.
BACKGROUND: Self-monitoring of blood glucose (SMBG) using the ColourSure™ Technology to visualize target range showed improvement of metabolic control and overall diabetes self-management in insulin-treated patients. This economic analysis aimed to identify cost savings for the German health system resulting from an HbA1c reduction due to the utilization of user-friendly glucose meters. METHODS:Patient data from a recently published observational study on SMBG were used for risk evaluations using the UKPDS risk engine. These values were integrated in an economic analysis regarding costs of myocardial infarctions (MIs) related to diabetes for the German health system. Based on an earlier assessment these calculations were combined with a 10% reduction of severe hypoglycemic episodes. In the current study, 0% severe hypoglycemic episodes were observed. RESULTS: An HbA1c reduction of 0.69% over 6 months was associated with a 3% decreased risk of MI in 10 years. In this model the decrease led to cost savings of €4.90 per patient-year. Considering 2.3 million insulin-treated patients in Germany, this 3% reduction of MI could result in annual savings of €11.27 million. Combining this with a 10% reduction in severe hypoglycemic events, the cost savings would increase to €30.61 per patient-year or €70.4 million for 2.3 million insulin-treated patients in Germany. CONCLUSION: The improvement of metabolic control and diabetes self-management that was achieved with the ColourSure™ Technology has the potential to generate substantial cost savings for the German health system underlining the importance of user-friendly methods for SMBG.
Entities:
Keywords:
ColourSure™ Technology; Diabetes; Economic Analysis; Self-Monitoring of Blood Glucose
Authors: G Veronese; G Marchesini; G Forlani; S Saragoni; L Degli Esposti; E Centis; A Fabbri Journal: Nutr Metab Cardiovasc Dis Date: 2016-01-18 Impact factor: 4.222
Authors: Viti Kothari; Richard J Stevens; Amanda I Adler; Irene M Stratton; Susan E Manley; H Andrew Neil; Rudy R Holman Journal: Stroke Date: 2002-07 Impact factor: 7.914
Authors: Elizabeth R Seaquist; John Anderson; Belinda Childs; Philip Cryer; Samuel Dagogo-Jack; Lisa Fish; Simon R Heller; Henry Rodriguez; James Rosenzweig; Robert Vigersky Journal: Diabetes Care Date: 2013-04-15 Impact factor: 19.112
Authors: Katharina Fritzen; Kornelia Basinska; Constantin Stautner; Karl F Braun; Matilde Rubio-Almanza; Antonio Nicolucci; Brian Kennon; Bruno Vergès; Yasser Hosny; Oliver Schnell Journal: J Diabetes Sci Technol Date: 2019-08-06